Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 10—October 2022
CME ACTIVITY - Synopsis

Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019

Emily RayensComments to Author , Mary Kay Rayens, and Karen A. Norris
Author affiliations: University of Georgia, Athens, Georgia, USA (E. Rayens, K.A. Norris); University of Kentucky, Lexington, Kentucky, USA (M.K. Rayens)

Main Article

Table

Number of risk conditions and fungal infections diagnosed among hospitalized patients, United States, 2019*

Fungal infections and risk conditions
 ICD-10 code
 No. cases diagnosed
Fungal infections
Aspergillosis B44 17,825
Invasive B44.0, B44.1, B44.7 8,875
Noninvasive B44.2, B44.8 4,210
Candidiasis B37 457,080
Invasive B37.1, B37.5, B37.6, B37.7 19,920
Noninvasive B37.0, B37.2, B37.3, B37.4, B37.8 396,765
Coccidioidomycosis B38 8,990
Cryptococcosis B45 4,900
Histoplasmosis B39 4,880
Mucormycosis B46 1,370
Pneumocystosis B59 9,725
Other B35, B36, B40–B43, B47, B48 145,925
Unspecified mycoses
 B49
 15,540
Risk conditions
Asthma J45–J46 2,273,360
Autoimmune conditions G35, G70, K90, L93, M05, M35 483,850
Cancer C00–C97 2,869,790
Chronic obstructive pulmonary disease J44 4,402,564
Cirrhosis K74 468,950
Cystic fibrosis E84 29,465
Diabetes mellitus E10–E14 8,376,979
End-stage renal disease D17 32,665
HIV B20–B24 109,180
Immunosuppressive disorders D80–D89 224,100
Influenza J09–J11 276,950
Myelodysplastic syndrome D46 82,170
Neutropenia D70 194,870
Osteomyelitis M86 385,450
Pneumonia J12–J18 2,552,504
Sepsis A40–A41 2,820,729
Transplant history Z94 266,580
Transplant complications T86 145,540
Tuberculosis A16–A19 3,690

*Data from ICD-10 codes listed in the Healthcare Cost and Utilization Project, 2019 (20). ICD-10, International Classification of Diseases, 10th Revision.

Main Article

References
  1. Bongomin  F, Gago  S, Oladele  RO, Denning  DW. Global and multi-national prevalence of fungal diseases–estimate precision. J Fungi (Basel). 2017;3:57. DOIPubMedGoogle Scholar
  2. Rayens  E, Norris  KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect Dis. 2022;9:ofab593.
  3. Rayens  E, Norris  KA, Cordero  JF. Mortality trends in risk conditions and invasive mycotic disease in the United States, 1999–2018. Clin Infect Dis. 2022;74:309–18. DOIPubMedGoogle Scholar
  4. Morris  A, Netravali  M, Kling  HM, Shipley  T, Ross  T, Sciurba  FC, et al. Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:e64–8. DOIPubMedGoogle Scholar
  5. Pilmis  B, Puel  A, Lortholary  O, Lanternier  F. New clinical phenotypes of fungal infections in special hosts. Clin Microbiol Infect. 2016;22:681–7. DOIPubMedGoogle Scholar
  6. Amin  R, Dupuis  A, Aaron  SD, Ratjen  F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137:171–6. DOIPubMedGoogle Scholar
  7. Rodrigues  CF, Rodrigues  ME, Henriques  M. Candida sp. infections in patients with diabetes mellitus. J Clin Med. 2019;8:76. DOIPubMedGoogle Scholar
  8. Ghanaat  F, Tayek  JA. Weight loss and diabetes are new risk factors for the development of invasive aspergillosis infection in non-immunocompromized humans. Clin Pract (Lond). 2017;14:296–301. DOIPubMedGoogle Scholar
  9. Vanderbeke  L, Spriet  I, Breynaert  C, Rijnders  BJA, Verweij  PE, Wauters  J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr Opin Infect Dis. 2018;31:471–80. DOIPubMedGoogle Scholar
  10. Coste  A, Frérou  A, Raute  A, Couturaud  F, Morin  J, Egreteau  P-Y, et al. The Extent of aspergillosis in critically ill patients with severe influenza pneumonia: a multicenter cohort study. Crit Care Med. 2021;49:934–42. DOIPubMedGoogle Scholar
  11. Bongomin  F. Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern. PLoS Pathog. 2020;16:e1008742. DOIPubMedGoogle Scholar
  12. Denning  DW, O’Driscoll  BR, Hogaboam  CM, Bowyer  P, Niven  RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006;27:615–26. DOIPubMedGoogle Scholar
  13. Rayens  E, Noble  B, Vicencio  A, Goldman  DL, Bunyavanich  S, Norris  KA. Relationship of Pneumocystis antibody responses to paediatric asthma severity. BMJ Open Respir Res. 2021;8:e000842. DOIPubMedGoogle Scholar
  14. Bishu  S, Su  EW, Wilkerson  ER, Reckley  KA, Jones  DM, McGeachy  MJ, et al. Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responses. Arthritis Res Ther. 2014;16:R50. DOIPubMedGoogle Scholar
  15. Silva  MF, Ferriani  MP, Terreri  MT, Pereira  RM, Magalhães  CS, Bonfá  E, et al. A multicenter study of invasive fungal infections in patients with childhood-onset systemic lupus erythematosus. J Rheumatol. 2015;42:2296–303. DOIPubMedGoogle Scholar
  16. Sipsas  NV, Kontoyiannis  DP. Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents. 2012;39:464–71. DOIPubMedGoogle Scholar
  17. Pappas  PG, Alexander  BD, Andes  DR, Hadley  S, Kauffman  CA, Freifeld  A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11. DOIPubMedGoogle Scholar
  18. Anderson  JL, Frost  HM, King  JP, Meece  JK. Racial differences in clinical phenotype and hospitalization of blastomycosis patients. Open Forum Infect Dis. 2019;6:ofz438. DOIPubMedGoogle Scholar
  19. Boehme  AK, McGwin  G, Andes  DR, Lyon  GM, Chiller  T, Pappas  PG, et al. Race and invasive fungal infection in solid organ transplant recipients. Ethn Dis. 2014;24:382–5.PubMedGoogle Scholar
  20. Agency for Healthcare Research and Quality. National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP) [cited 2022 Jan 14]. https://www.hcup-us.ahrq.gov/nisoverview.jsp
  21. US Census Bureau. American community survey data 2006–2010 [cited 2022 Jan 14]. https://www.census.gov/programs-surveys/acs/data.html
  22. Stranges  E, Holmquist  L, Andrews  RM; Agency for Healthcare Research and Quality. Inpatient stays in rural hospitals, 2007: statistical brief #85. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): The Agency; 2006.
  23. El-Nahal  W. An overview of Medicare for clinicians. J Gen Intern Med. 2020;35:3702–6. DOIPubMedGoogle Scholar
  24. Hill  SC, Abdus  S. The effects of Medicaid on access to care and adherence to recommended preventive services. Health Serv Res. 2021;56:84–94. DOIPubMedGoogle Scholar
  25. Rodriguez  A, Brickley  E, Rodrigues  L, Normansell  RA, Barreto  M, Cooper  PJ. Urbanisation and asthma in low-income and middle-income countries: a systematic review of the urban-rural differences in asthma prevalence. Thorax. 2019;74:1020–30. DOIPubMedGoogle Scholar
  26. Egger  M, Hoenigl  M, Thompson  GR III, Carvalho  A, Jenks  JD. Let’s talk about sex characteristics-As a risk factor for invasive fungal diseases. Mycoses. 2022;65:599–612. DOIPubMedGoogle Scholar
  27. vom Steeg  LG, Klein  SL. SeXX matters in infectious disease pathogenesis. PLoS Pathog. 2016;12:e1005374. DOIPubMedGoogle Scholar
  28. Khan  A, Marks  S, Katz  D, Morris  SB, Lambert  L, Magee  E, et al. Changes in tuberculosis disparities at a time of decreasing tuberculosis incidence in the United States, 1994–2016. Am J Public Health. 2018;108(S4):S321–6. DOIPubMedGoogle Scholar
  29. Wesselman  H, Ford  CG, Leyva  Y, Li  X, Chang  CH, Dew  MA, et al. Social determinants of health and race disparities in kidney transplant. Clin J Am Soc Nephrol. 2021;16:262–74. DOIPubMedGoogle Scholar
  30. Hong  S, Rybicki  L, Abounader  DM, Bolwell  BJ, Dean  R, Gerds  AT, et al. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma. Bone Marrow Transplant. 2016;51:1191–6. DOIPubMedGoogle Scholar
  31. Kerem  E, Cohen-Cymberknoh  M. Disparities in cystic fibrosis care and outcome: socioeconomic status and beyond. Chest. 2016;149:298–300. DOIPubMedGoogle Scholar
  32. Grehn  C, Eschenhagen  P, Temming  S, Düesberg  U, Neumann  K, Schwarz  C. Urban life as risk factor for aspergillosis. Front Cell Infect Microbiol. 2020;10:601834. DOIPubMedGoogle Scholar
  33. Strollo  S, Lionakis  MS, Adjemian  J, Steiner  CA, Prevots  DR. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerg Infect Dis. 2016;23:7–13. DOIPubMedGoogle Scholar
  34. Barnett  ML, Hsu  J, McWilliams  JM. Patient characteristics and differences in hospital readmission rates. JAMA Intern Med. 2015;175:1803–12. DOIPubMedGoogle Scholar
  35. Stanbury  M, Rosenman  KD. Occupational health disparities: a state public health-based approach. Am J Ind Med. 2014;57:596–604. DOIPubMedGoogle Scholar
  36. McCurdy  SA, Portillo-Silva  C, Sipan  CL, Bang  H, Emery  KW. Risk for coccidioidomycosis among Hispanic farm workers, California, USA, 2018. Emerg Infect Dis. 2020;26:1430–7. DOIPubMedGoogle Scholar
  37. Kassis  C, Durkin  M, Holbrook  E, Myers  R, Wheat  L. Advances in diagnosis of progressive pulmonary and disseminated coccidioidomycosis. Clin Infect Dis. 2021;72:968–75. DOIPubMedGoogle Scholar
  38. Kupferwasser  D, Miller  LG. Sociodemographic factors associated with patients hospitalised for coccidioidomycosis in California and Arizona, State Inpatient Database 2005-2011. Epidemiol Infect. 2020;149:e127. DOIPubMedGoogle Scholar
  39. Armstrong  PA, Jackson  BR, Haselow  D, Fields  V, Ireland  M, Austin  C, et al. Multistate epidemiology of histoplasmosis, United States, 2011–2014. Emerg Infect Dis. 2018;24:425–31. DOIPubMedGoogle Scholar
  40. Benedict  K, McCracken  S, Signs  K, Ireland  M, Amburgey  V, Serrano  JA, et al. Enhanced surveillance for histoplasmosis—9 states, 2018–2019. Open Forum Infect Dis. 2020;7:ofaa343.
  41. McCree  DH, Williams  AM, Chesson  HW, Beer  L, Jeffries  WL IV, Lemons  A, et al. Changes in disparities in estimated HIV incidence rates among Black, Hispanic/Latino, and White men who have sex with men (MSM) in the United States, 2010–2015. J Acquir Immune Defic Syndr. 2019;81:57–62. DOIPubMedGoogle Scholar
  42. George  IA, Spec  A, Powderly  WG, Santos  CAQ. Comparative epidemiology and outcomes of human immunodeficiency virus (HIV), non-HIV non-transplant, and solid organ transplant associated cryptococcosis: a population-based study. Clin Infect Dis. 2018;66:608–11. DOIPubMedGoogle Scholar
  43. Prakash  H, Chakrabarti  A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5:26. DOIPubMedGoogle Scholar
  44. Loo  DS. Cutaneous fungal infections in the elderly. Dermatol Clin. 2004;22:33–50. DOIPubMedGoogle Scholar
  45. Barchiesi  F, Orsetti  E, Mazzanti  S, Trave  F, Salvi  A, Nitti  C, et al. Candidemia in the elderly: What does it change? PLoS One. 2017;12:e0176576. DOIPubMedGoogle Scholar
  46. Dignani  MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep. 2014;6:81. DOIPubMedGoogle Scholar

Main Article

Page created: August 11, 2022
Page updated: September 21, 2022
Page reviewed: September 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external